A clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain.
Lead Underwriter
Cantor Fitzgerald & Co., Evercore Group L.L.C, William Blair & Company, L.L.C.
Co-Managers
Berenberg Capital Markets, LLC, H.C. Wainwright & Co., LLC
